Prosecution Insights
Last updated: October 25, 2026

Longping Biotech (Hainan) Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Longping Biotech (Hainan) Co. Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is handled by 1 examiner in 1 art unit, so the reported prosecution activity is concentrated.

ZHONG, WAYNESHAOBIN is the listed examiner and has 1 pending matter. A focused response strategy can address the complete reported docket without coordinating across separate assignments.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
1
Easy (100%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ZHONG, WAYNESHAOBIN 1 72.3% +21.4%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18699269 TRANSGENIC MAIZE EVENT LP026-2 AND DETECTION METHOD THEREFOR ZHONG, WAYNESHAOBIN —

Top Art Units

Art UnitApps
1662 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18699269 TRANSGENIC MAIZE EVENT LP026-2 AND DETECTION METHOD THEREFOR ZHONG, WAYNESHAOBIN 1662 §112 Final Rejection — Pending Apr 06, 2024

Managing Longping Biotech (Hainan) Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Longping Biotech (Hainan) Co. Ltd. have?

Longping Biotech (Hainan) Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Longping Biotech (Hainan) Co. Ltd. applications?

Wayneshaobin Zhong has the most, with 1 of Longping Biotech (Hainan) Co. Ltd.'s pending office actions.

What technology area are Longping Biotech (Hainan) Co. Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month